Panacea Sciences

Panacea Sciences The Art & Science of Female Hormone Medicine specializes in female HRT training, hormone practice consulting, and female hormone balancing.

Panacea Sciences is health sciences and biotechnology company founded in 2014 by Marie Hoäg, MBA that specializes in hormone, endocrine, and estrogen research, hormone replacement therapy (HRT) development, professional education & clinical application training, and treatments in advanced natural hormone restoration therapies for women.

In the hormone clinic, we found that counting calories is less effective for weight loss than intermittent fasting and c...
04/14/2025

In the hormone clinic, we found that counting calories is less effective for weight loss than intermittent fasting and counting carbs.

Intermittent fasting also helps restore hormonal balance for women on advanced HRT protocols.

Here is an excellent article about it.



Background: Long-term (≥12 months) randomized trials evaluating the efficacy of intermittent fasting (IMF) as a dietary weight loss strategy are limited. Furthermore, no studies have compared IMF versus daily caloric restriction (DCR) when both interventions are provided in the context of a guidel...

Hormone therapy (HT) can help women manage menopause symptoms into their 80s, and the reasons are varied, according to a...
11/07/2024

Hormone therapy (HT) can help women manage menopause symptoms into their 80s, and the reasons are varied, according to a retrospective analysis being presented at the annual meeting of The Menopause Society.

"It's important to know that this is a preselected group of women who had no contraindications to continuing their hormone therapy," senior author Wendy Wolfman, MD, director of the Menopause Clinic and The Premature Ovarian Insufficiency Clinic at Mount Sinai Hospital in Toronto, Ontario, Canada, said in an interview. "They had the initiation of hormone therapy closer to menopause and carried on their hormones. We followed them for a long time and basically saw no real concerns about taking the hormones and the patients did very well. It's important to emphasize this was not the new initiation of hormone therapy in elderly women."

Scans comparing women at different menopausal stages revealed progressively higher ER density in several estrogen-regula...
10/07/2024

Scans comparing women at different menopausal stages revealed progressively higher ER density in several estrogen-regulated brain networks in the postmenopausal and perimenopausal groups compared to premenopausal controls.

The researchers interpret this as a compensatory response to waning levels of available estrogen— as estrogen levels drop during the menopause transition, the cells express additional receptors to sop up as much estrogen as possible.



The transition to menopause is marked by a progressively higher density of estrogen receptors (ER) on brain cells, a measure that remains elevated in women up to their mid-60s, according to a new brain imaging study led by researchers at Weill Cornell Medicine.

Women benefit from estrogen no matter how old they are. According to Menopause the journal of the Menopause Society.Comp...
06/26/2024

Women benefit from estrogen no matter how old they are. According to Menopause the journal of the Menopause Society.

Compared with never use or discontinuation of menopausal hormone therapy after age 65 years, the use of estrogen monotherapy beyond age 65 years was associated with significant risk reductions in mortality (19% or adjusted hazards ratio, 0.81; 95% CI, 0.79-0.82), breast cancer (16%), lung cancer (13%), colorectal cancer (12%), congestive heart failure (CHF) (5%), venous thromboembolism (3%), atrial fibrillation (4%), acute myocardial infarction (11%), and dementia (2%). For the use of estrogen and progestogen combo-therapy, both E+ progestin and E+ progesterone were associated with increased risk of breast cancer by 10%-19%, but such risk can be mitigated using low dose of transdermal or vaginal E+ progestin. Moreover, E+ progestin exhibited significant risk reductions in endometrial cancer (45% or adjusted hazards ratio, 0.55; 95% CI, 0.50-0.60), ovarian cancer (21%), ischemic heart disease (5%), CHF (5%), and venous thromboembolism (5%), whereas E+ progesterone exhibited risk reduction only in CHF (4%).



en from 2007-2020 and Cox regression analyses adjusted for time-varying characteristics of the women, we examined the effects of different preparations of menopausal hormone therapy on all-cause mortality, five cancers, six cardiovascular diseases, and dementia. Results Compared with never use or di...

The constant ebb and flow of hormones that guide the menstrual cycle don't just affect reproductive anatomy. They also r...
06/26/2024

The constant ebb and flow of hormones that guide the menstrual cycle don't just affect reproductive anatomy. They also reshape the brain, and a study has given us insight into how this happens.

Led by neuroscientists Elizabeth Rizor and Viktoriya Babenko of the University of California Santa Barbara, a team of researchers tracked 30 women who menstruate over their cycles, documenting in detail the structural changes that take place in the brain as hormonal profiles fluctuate.

The results, which are yet to be peer-reviewed but can be found on preprint server bioRxiv, suggest that structural changes in the brain during menstruation may not be limited to those regions associated with the menstrual cycle.



The constant ebb and flow of hormones that guide the menstrual cycle don't just affect reproductive anatomy.

5600 women with hypoestrogenism who were prescribed vaginal estrogen for the prevention of recurrent urinary tract infec...
10/02/2023

5600 women with hypoestrogenism who were prescribed vaginal estrogen for the prevention of recurrent urinary tract infections, the frequency of urinary tract infection decreased by more than 50% in the following year. Baseline urinary tract infection frequency, increasing age, urinary incontinence or retention, and diabetes were associated with an increased risk of postprescription urinary tract infection. The paradoxical finding that women with moderate and high medication adherence experienced the lowest-magnitude reduction in urinary tract infection frequency may represent unobserved selection or unmeasured confounding.

In this retrospective review of 5600 women with hypoestrogenism who were prescribed vaginal estrogen for the prevention of recurrent urinary tract infections, the frequency of urinary tract infection decreased by more than 50% in the following year. Baseline urinary tract infection frequency, increa...

Women who reported to have s*x weekly during the study period were 28% less likely to experience menopause than women wh...
08/28/2023

Women who reported to have s*x weekly during the study period were 28% less likely to experience menopause than women who had s*x less than monthly.

It is often observed that married women have a later age of natural menopause (ANM) than unmarried women; however, the reason for this association is unknown. We test an original hypothesis that s*xual frequency acts as a bio-behavioural mediator between ...

Although the lack of estrogen receptor β (ERβ) is a risk factor for the development of inflammatory bowel disease (IBD) ...
05/18/2023

Although the lack of estrogen receptor β (ERβ) is a risk factor for the development of inflammatory bowel disease (IBD) and psychiatric disorders, the underlying cellular and molecular mechanisms are not fully understood. Herein, we revealed the role of gut microbiota in the development of IBD and related anxiety-like behavior in ERβ-deficient mice.

Background Although the lack of estrogen receptor β (ERβ) is a risk factor for the development of inflammatory bowel disease (IBD) and psychiatric disorders, the underlying cellular and molecular mechanisms are not fully understood. Herein, we revealed the role of gut microbiota in the development...

The microbiota is now recognized as one of the major players in human health and diseases, including cancer. Regarding b...
04/27/2023

The microbiota is now recognized as one of the major players in human health and diseases, including cancer. Regarding breast cancer (BC), a clear link between microbiota and oncogenesis still needs to be confirmed. Yet, part of the bacterial gene mass inside the gut, constituting the so called “estrobolome”, influences s*xual hormonal balance and, since the increased exposure to estrogens is associated with an increased risk, may impact on the onset, progression, and treatment of hormonal dependent cancers (which account for more than 70% of all BCs). The hormonal dependent BCs are also affected by environmental and dietary endocrine disruptors and phytoestrogens which interact with microbiota in a bidirectional way: on the one side disruptors can alter the composition and functions of the estrobolome, ad on the other the gut microbiota influences the metabolism of endocrine active food components. This review highlights the current evidence about the complex interplay between endocrine disruptors, phytoestrogens, microbiome, and BC, within the frames of a new “oncobiotic” perspective.

The microbiota is now recognized as one of the major players in human health and diseases, including cancer. Regarding breast cancer (BC), a clear link between microbiota and oncogenesis still needs to be confirmed. Yet, part of the bacterial gene mass inside the gut, constituting the so called &ldq...

Address

5 Williamsburg Lane
Los Angeles, CA
95926

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 3pm
Saturday 12pm - 3pm

Telephone

+13232859494

Alerts

Be the first to know and let us send you an email when Panacea Sciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Menopause Prevention Protocols

Panacea Sciences is a health sciences and biotechnology company founded in 2014 by Marie Hoäg, MBA that specializes in:

· Estrogen, Hypoestrogenism, and Estrogen Deficiency Disease Research

· Advanced female hormone replacement therapy (HRT) clinical protocol development

· Advanced female HRT education and clinical application training